SP2

Across TCGA pan-cancer cohorts, SP2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SP2 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SP2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SP2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

PDAC, LSCC, and LUAD are the cancer types where SP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.950	0.747	<.001	70	view →
LSCC	OS	Quartile	All	0.954	0.629	.001	33	view →
LUAD	DFS	Quartile	III,IV	0.266	0.916	.006	13	view →
CCRCC	DFS	Median	III,IV	0.696	0.455	.017	6	view →
HNSC	DFS	Tertile	III,IV	0.495	0.730	.032	5	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SP2–PDAC (DFS)

Open the PDAC breakdown →